Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against neisseria meningitidis group B

Infection and Immunity

Volumn 79, Issue 10, 2011, Pages 4146-4156

  Schmiel, Deborah H ^a   Moran, Elizabeth E ^a   Keiser, Paul B ^a   Brandt, Brenda L ^a,b   Zollinger, Wendell D ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; CROSS REACTING ANTIBODY; CYTIDINE PHOSPHATE N ACETYLNEURAMINIC ACID; EPITOPE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CONVALESCENCE; HUMAN; INFANT; INNATE IMMUNITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SERUM BACTERICIDAL ACTIVITY; SIALYLATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; DOUBLE-BLIND METHOD; HUMANS; INFANT; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80855136568     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05125-11     Document Type: Article

References (67)

1. Andersen, R. S., et al. 1997. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb. Pathog. 23:139-155.
2. Babcock, J., et al. 2003. Phase I study of meningococcal outer membrane protein-detoxified lipooligosaccharide vaccine in liposomes, poster P10. Abstr. Sixth Ann. Conf. Vaccine Res., Arlington, VA.
3. Baumgarth, N., J. W. Tung, and L. A. Herzenberg. 2005. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin. Immunopathol. 26:347-362.
4. Berrington, A. W., et al. 2002. Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunol. Med. Microbiol. 34:267-275.
5. Bishop, A. L., S. Schild, B. Patimalla, B. Klein, and A. Camilli. 2010. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect. Immun. 78:4402-4420.
6. Boslego, J., et al. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829.
7. Brandtzaeg, P., et al. 2001. Neisseria meningitidis lipopolysaccharides in human pathology. J. Endotoxin Res. 7:401-420.
8. Burnette, W. N. 1981. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112:195-203.
9. Choudhury, B., C. M. Kahler, A. Datta, D. S. Stephens, and R. W. Carlson. 2008. The structure of the L9 immunotype lipooligosaccharide from Neisseria meningitidis NMA Z2491. Carbohydr. Res. 343:2971-2979.
10. Cox, A. D., et al. 2005. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Vaccine 23:5045-5054.
11. Cross, A. S., et al. 2003. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21:4576-4587.
12. Drabick, J. J., et al. 1999. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 18:160-172.
13. Estabrook, M. M., G. A. Jarvis, and J. M. Griffiss. 2007. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect. Immun. 75:1025-1033.
14. Fredriksen, J. H., et al. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-79. (Discussion, 14:79-80.)
15. Frasch, C. E., W. D. Zollinger, and J. T. Poolman. 1985. A proposed nomenclature for designation of serotypes within Neisseria meningitidis. Rev. Infect. Dis. 7:504-510.
16. Gamian, A., M. Beurret, F. Michon, J. R. Brisson, and H. J. Jennings. 1992. Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J. Biol. Chem. 267:922-925.
17. Gold, R., M. L. Lepow, I. Goldschneider, T. L. Draper, and E. C. Gotschlich. 1975. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest. 175:1536-1547.
18. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
19. Griffiss, J. M., B. L. Brandt, D. D. Broud, D. K. Goroff, and C. J. Baker. 1984. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis. 150:71-79.
20. Griffiss, J. M., B. L. Brandt, N. B. Saunders, and W. Zollinger. 2000. Structural relationships and sialylation among meningococcal L1, L8, and L3,7 lipooligosaccharide serotypes. J. Biol. Chem. 275:9716-9724.
21. Gu, X.-X., et al. 1997. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect. Immun. 65:4488-4493.
22. Gu, X. X., and C. M. Tsai. 1993. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharideprotein conjugates. Infect. Immun. 61:1873-1880.
23. Jäkela, A., et al. 2008. Naturally occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures. Vaccine 26:6655-6663.
24. Jennings, H. J., A. K. Bhattacharjee, L. Kenne, C. P. Kenny, and G. Calver. 1980. The R-type lipopolysaccharides of Neisseria meningitidis. Can. J. Biochem. 58:128-136.
25. Kahler, C. M., A. Datta, Y. L. Tzeng, R. W. Carlson, and D. S. Stephens. 2005. Inner core assembly and structure of the lipooligosaccharide of Neisseria meningitidis: capacity of strain NMB to express all known immunotype epitopes. Glycobiology 15:409-419.
26. Kahler, C. M., and D. S. Stephens. 1998. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit. Rev. Microbiol. 24:281-334.
27. Karkhanis, Y. D., J. Y. Zeltner, J. J. Jackson, and D. J. Carlo. 1978. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal. Biochem. 85:595-601.
28. Keiser, P. B., et al. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
29. Kim, J. J., N. J. Phillips, B. W. Gibson, J. M. Griffiss, and R. Yamasaki. 1994. Meningococcal group A lipooligosaccharides (LOS): preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes. Infect. Immun. 62:1566-1575.
30. Koeberling, O., I. Delany, and D. M. Granoff. 2011. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Infect. Immun. 18:736-742.
31. Kurzai, O., et al. 2005. Carbohydrate composition of meningococcal lipopolysaccharide modulates the interaction of Neisseria meningitidis with human dendritic cells. Cell. Microbiol. 7:1319-1334.
32. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
33. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
34. Mandrell, R. E., J. M. Griffiss, and B. A. Macher. 1988. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J. Exp. Med. 168:107-126. (Erratum, 168:1517.)
35. Mandrell, R. E., et al. 1991. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J. Bacteriol. 173:2823-2832.
36. Mandrell, R. E., and W. D. Zollinger. 1977. Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition. Infect. Immun. 16:471-475.
37. Michon, F., M. Beurret, A. Gamian, J. R. Brisson, and H. J. Jennings. 1990. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J. Biol. Chem. 265:7243-7247.
38. Mistretta, N., et al. 2010. Genetic and structural characterization of L11 lipooligosaccharide from Neisseria meningitidis serogroup A strains. J. Biol. Chem. 285:19874-19883.
39. Orr, N., G. Robin, D. Cohen, R. Arnon, and G. H. Lowell. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61:2390-2395.
40. Passwell, J. H., et al. 1995. Shigella lipopolysaccharide antibodies in pediatric populations. Pediatr. Infect. Dis. J. 14:859-865.
41. Pavliak, V., M. Fortuna-Nevin, M. Monteiro, K. Mason, and D. Zhu. 2004. Neisseria meningitidis LOS conjugate vaccine against meningococcal disease, abstr. 8. Abstr. 14th Int. Pathog. Neisseria Conf., Milwaukee, WI.
42. Pavliak, V., J. R. Brisson, F. Michon, D. Uhrín, and H. J. Jennings. 1993. Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis. J. Biol. Chem. 268:14146-14152.
43. Plested, J. S., and D. M. Granoff. 2008. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin. Vaccine Immunol. 15:799-804.
44. Rahman, M. M., D. S. Stephens, C. M. Kahler, J. Glushka, and R. W. Carlson. 1998. The lipooligosaccharide (LOS) of Neisseria meningitidis serogroup B strain NMB contains L2, L3, and novel oligosaccharides, and lacks the lipid-A 4'-phosphate substituent. Carbohydr. Res. 307:311-324.
45. Reid, R. R., et al. 1997. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159:970-975.
46. Saunders, N. B., et al. 1999. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67:113-119.
47. Snapper, C. M. 2006. Differential regulation of proteinand polysaccharidespecific Ig isotype production in vivo in response to intact Streptococcus pneumoniae. Curr. Protein Pept. Sci. 7:295-305.
48. Tappero, J. W., et al. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
49. Tong, Y., V. Reinhold, B. Reinhold, B. Brandt, and D. C. Stein. 2001. Structural and immunochemical characterization of the lipooligosaccharides expressed by Neisseria subflava 44. J. Bacteriol. 183:942-950.
50. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
51. Unkmeir, A., et al. 2002. Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect. Immun. 70:2454-2462.
52. Verheul, A. F., et al. 1991. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect. Immun. 59:843-851.
53. Vogel, U., S. Hammerschmidt, and M. Frosch. 1996. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med. Microbiol. Immunol. 185:81-87.
54. Wedege, E., E. A. Høiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231.
55. Westphal, O., O. Luderitz, and F. Bister. 1952. Uber die Extraktion von bakterien mit Phenol/Wasser. Z. Naturforsch. B 7:148-155.
56. Weynants, V., et al. 2009. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 77:2084-2093.
57. Weynants, V. E., et al. 2007. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun. 75:5434-5442.
58. Yu, S., and X.-X. Gu. 2007. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect. Immun. 75:2974-2980.
59. Zhou, Z. H., et al. 2007. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 15:51-61.
60. Zhu, P., et al. 2002. Genetic diversity of three lgt loci for biosynthesis of lipooligosaccharide (LOS) in Neisseria species. Microbiology 148:1833-1844.
61. Zollinger, W. D., et al. 17 November 1987. Process for the preparation of detoxified polysaccharide-outer membrane protein complexes and their use as antibacterial vaccines. U.S. patent 4,707,543.
62. Zollinger, W., et al. 2010. Design and evaluation in animals of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28:5057-5067.
63. Zollinger, W. D., and R. E. Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.
64. Zollinger, W. D., and R. E. Mandrell. 1980. Type-specific antigens of group A Neisseria meningitidis: lipopolysaccharide and heat-modifiable outer membrane proteins. Infect. Immun. 28:451-458.
65. Zollinger, W. D., E. E. Moran, J. Ray, and B. McClain. 1991. Phase I safety and immunogenicity study of a meningococcal outer membrane protein detoxified LPS vaccine. Abstr. Front. Vaccine Res., Helsinki, Finland.
66. Zollinger, W. D., E. E. Moran, and D. H. Schmiel. 2009. Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity. Clin. Vaccine Immunol. 16:1789-1795.
67. Zollinger, W. D., D. Shoemaker, A. G. Saunders, and B. L. Brandt. 6 May 2003. Vaccine against gram negative bacteria. U.S. patent 6,558,677 B2.